Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice

Clinical Cancer Research

Volumn 13, Issue 18, 2007, Pages 5480-5487

  Zheng, Xi ^a   Cui, Xiao Xing ^a   Avila, Gina E ^a   Huang, Mou Tuan ^a   Liu, Yue ^a   Patel, Jagruti ^a   Kong, Ah Ng Tony ^a   Paulino, Raphael ^a   Weichung, Joe Shih ^c,d   Lin, Yong ^c,d   Rabson, Arnold B ^b,d   Reddy, Bandaru S ^a   Conney, Allan H ^a,d  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CELECOXIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL STRAIN; CELL STRAIN PC 3; CONTROLLED STUDY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; SCID MOUSE; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CYCLOOXYGENASE INHIBITORS; DRUG THERAPY, COMBINATION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, SCID; PROSTATIC NEOPLASMS; PYRAZOLES; PYRROLES; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34848893709     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0242     Document Type: Article

References (33)

1. Berg JW, Hajdu SI, Foote FW, Jr. The prevalence of latent cancers in cancer patients. Arch Pathol Lab Med 1971;91:183-6.
2. Franks LM. Latent carcinoma of the prostate. J Pathol Bacteriol 1954;68:603-16.
3. Segi M, Fujisaku S, Kurihara M. Geographical comparison of deaths from malignant neoplasms; a study of age-adjusted death rates for malignant neoplasms in various countries. Acta Unio Int Contra Cancrum 1958;14:591-8.
4. Karube K. Study of latent carcinoma of the prostate in the Japanese based on necropsy material. Tohoku J Exp Med 1961;74:265-85.
5. Morrissey C, Vessella RL. The role of tumor microenvironment in prostate cancer bone metastasis. J Cell Biochem 2007;101:873-86.
6. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003;63:1684-95.
7. Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol 1998;82:3-10J.
8. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Clinical review 145: pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002;87:1451-8.
9. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol 2004;22:2388-94.
10. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000;160:2363-8.
11. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004;90:635-7.
12. Shannon J, Tewoderos S, Garzotto M, et al. Statins and prostate cancer risk: a case-control study. Am J Epidemiol 2005;162:318-25.
13. Moyad MA, Merrick GS, Butler WM, et al. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 2005;66:1150-4.
14. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005;115:959-68.
15. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 2004;64:6461-8.
16. Gupta S, Adhami VM, Subbarayan M, et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2004;64:3334-43.
17. Narayanan BA, Narayanan NK, Pittman B, Reddy BS. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 2004;10:7727-37.
18. Pruthi RS, Derksen JE, Moore D. A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU Int 2004;93:275-8.
19. Reddy BS, Wang CX, Kong AN, et al. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 2006;66:4542-6.
20. Motyl T, Grzelkowska K, Zimowska W, et al. Expression of bcl-2 and bax in TGF-β1-induced apoptosis of L1210 leukemic cells. Eur J Cell Biol 1998;75:367-74.
21. Xu C, Shen G, Chen C, Gelinas C, Kong AN. Suppression of NF-κB and NF-κB-regulated gene expression by sulforaphane and PEITC through IκBα, IKK pathway in human prostate cancer PC-3 cells. Oncogene 2005;24:4486-95.
22. Zheng X, Chang RL, Cui XX, et al. Inhibitory effect of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans-retinoic acid on the growth of LNCaP prostate tumors in immunodeficient mice. Cancer Res 2004;64:1811-20.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
24. Lindsey JK. Models for repeated measurements. Oxford: Claredon Press; 1993.
25. Hsu JC. Multiple comparisons: theory and methods. New York: Chapman and Hall; 1996.
26. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
27. Edwards PA, Ericsson J. Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu Rev Biochem 1999;68:157-85.
28. Weber MJ, Gioeli D. Ras signaling in prostate cancer progression. J Cell Biochem 2004;91:13-25.
29. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Jr., Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 1999;59:279-84.
30. Uzgare AR, Isaacs JT. Prostate cancer: potential targets of anti-proliferative and apoptotic signaling pathways. Int J Biochem Cell Biol 2005;37:707-14.
31. Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. Arthritis Rheum 2006;54:3390-8.
32. Solomon SD, Pfeffer MA, McMurray JJ, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006;114:1028-35.
33. Suh J, Rabson AB. NF-κB activation in human prostate cancer: important mediator or epiphenomenon? J Cell Biochem 2004;91:100-17.